ARCT Share Price Performance
US$8.63
-4.20 (-32.74%)
7.9% overvalued intrinsic discount
US$8.00
Fair Value
Price US$8.63
AnalystLowTarget US$8.00
AnalystHighTarget US$54.97
Fair ValueUS$8.00
Share Pricen/a
Arcturus Therapeutics Holdings Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 72 Fair Values set on narratives written by author
ARCT Community Narratives
AN
Fair Value
·Fair Value US$8 7.9% overvalued intrinsic discount
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$54.97 84.3% undervalued intrinsic discount
Self-amplifying mRNA Will Meet Aging Global Therapy Demand
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Self-amplifying mRNA Will Meet Aging Global Therapy Demand
Key Takeaways Unique mRNA platform enables rapid market expansion and premium positioning in vaccines, with strong potential for high-margin, recurring revenues and first-mover advantages. Operational efficiency and breakthrough pipeline support sustainable growth, while industry trends drive significant partnering and shareholder value-creation opportunities.Read more
AN
US$54.97
84.3% undervalued intrinsic discount
Fair Value
Profit Margin
52.64%
Future PE
5.3x
Price in 2029
US$66.46
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
Key Takeaways Heavy reliance on a few clinical programs and uncertain commercialization timelines create considerable risk for sustained revenue and earnings growth. Elevated cash burn, history of losses, and potential delays in partnerships heighten the risk of future dilution or unprofitable expansion.Read more
AN
US$8
7.9% overvalued intrinsic discount
Fair Value
Profit Margin
14.82%
Future PE
156x
Price in 2029
US$9.67
Trending Discussion
Recently Updated Narratives
AN
ARCT: CF And OTCD Pipeline Progress Will Support Future Share Price Upside
Fair Value: US$54.97 84.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARCT: Future Execution Risks Will Drive Sensitivity To Pipeline Milestones
Fair Value: US$8 7.9% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcturus Therapeutics Holdings Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 07, 2026
- -2.31
- -36.79%
- -80.19%
- 0%
About ARCT
- Founded
- 2013
- Employees
- 109
- CEO
- WebsiteView website
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
